Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.7%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) fell 5.7% during mid-day trading on Wednesday . The company traded as low as $13.55 and last traded at $13.66. 9,529 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 15,401 shares. The stock had previously closed at $14.48.

Analyst Upgrades and Downgrades

Separately, HC Wainwright began coverage on shares of Aligos Therapeutics in a report on Monday. They issued a “buy” rating and a $75.00 price objective for the company.

Aligos Therapeutics Stock Performance

The business’s fifty day moving average is $12.17 and its 200-day moving average is $17.18. The firm has a market cap of $1.08 billion, a P/E ratio of -10.81 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative return on equity of 144.16%. During the same quarter last year, the business earned ($10.75) EPS. Analysts predict that Aligos Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALGS. Armistice Capital LLC raised its holdings in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. bought a new position in Aligos Therapeutics during the 4th quarter worth approximately $1,889,000. Opaleye Management Inc. raised its holdings in Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in Aligos Therapeutics by 26.1% during the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).